ASX copper stocks have recorded 3 big hits this week

Nick Sundich Nick Sundich, November 4, 2022

ASX copper stocks have not been as popular with investors as lithium stocks recently. Copper has been plagued by China’s COVID zero policy and rising interest rates. But there have been some notable hits made by ASX copper explorers this week.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Norfolk Metals leads the charge

Tasmanian-focused explorer Norfolk Metals (ASX:NFL) yesterday reported the intersection of native copper in the maiden drill test at its Roger River Project.

These were not formal assay results, these are coming in December. But the company did intersect visible copper and, in doing so in the first drilling hole, shareholders hope that further results will continue to deliver.

 

Other ASX copper hits this week 

Another solid result from an ASX copper stock came from American West (ASX:AW1). The Canadian focused explorer recorded assay results of 19m @ 2.08%, including 2m at 15.98% copper.

And this morning, Cosmo Metals (ASX:CMO) reported results from its Mt. Venn project in Western Australia: 13m @ 0.46% copper, including 1m @ 1.27% copper. Typically, any copper grade below 1.3% is considered lower grade. But it appears shareholders are willing to forgive this given WA’s lower sovereign risk.

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Nuix

Nuix (ASX:NXL) has quadrupled in 12 months! But is more growth to come?

Nuix (ASX:NXL) has been one of the most controversial companies on the ASX since it listed, but has it turned…

ASX Biotechs

Here are 3 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…

buy the dip

When do you know it’s time to ‘buy the dip’? You could be catching a falling knife

‘Buy the dip’ – have you ever heard that term? It implies that when a company’s share price ‘dips’ or decreases,…